Biodesix 2025 Q2 Earnings Revenue Grows 11.7% Amid Expanding Losses

Biodesix reported mixed results in its Q2 2025 earnings, with revenue growth outpacing expectations, though net losses expanded. The company reaffirmed its full-year revenue guidance and highlighted strategic progress in key areas.

Revenue

Biodesix reported total revenue of $20.02 million in Q2 2025, reflecting an 11.7% year-over-year increase. Diagnostic Tests remained the core revenue driver, contributing $17.90 million, while the Development Services segment added $2.12 million, marking strong performance across both business lines.

Earnings/Net Income

The company maintained a negative EPS of $-0.08 for the quarter, consistent with the prior year. Net losses, however, widened to $11.47 million, a 6.1% increase from $10.81 million in Q2 2024. These figures underscore the ongoing financial challenges, with the company reporting losses for six consecutive years during the same quarter.

Price Action

Biodesix shares experienced a sharp upward movement in the month following the earnings report, surging 52.04% month-to-date. The stock gained 27.10% during the most recent full trading week and rose 9.83% on the latest trading day, suggesting strong investor sentiment despite earnings results.

Post-Earnings Price Action Review

A strategy of purchasing Biodesix shares following the Q2 2025 earnings report and holding for 30 days proved highly unprofitable, returning -81.82% over the past three years. The approach underperformed the benchmark by 129.73% and had a Sharpe ratio of -0.45, indicating a high-risk, low-reward profile. Additionally, the strategy faced a maximum drawdown of 0%, indicating no recovery opportunity.

CEO Commentary

Scott Hutton, CEO of Biodesix, highlighted the company’s 12% revenue growth and 80% gross margin in Q2. He emphasized progress in expanding into primary care physicians, which led to a significant increase in lung diagnostic test orders. Hutton also noted a 53% year-over-year revenue growth in the Development Services business and a 54% increase in dollars under contract. He expressed confidence in achieving Adjusted EBITDA positivity by Q4 and reiterated the importance of sales team expansion and operational improvements.

Guidance

Biodesix reaffirmed its full-year 2025 revenue guidance of $80–85 million. Hutton expressed optimism about the company’s long-term growth potential and operational momentum, with no downward revisions to prior expectations.

Additional News

Recent global developments include heightened tensions over the Gaza plan, as diplomatic rifts emerge ahead of key cabinet meetings. India has pushed back after recent trade policy adjustments, while the U.S. and China continue to emphasize the importance of stable relations. In the Americas, former President Trump announced the nomination of a key economic adviser to the Federal Reserve and ordered the exclusion of undocumented immigrants from the 2020 census. Meanwhile, in Europe, Portugal extended its national alert due to severe wildfires, and the EU faces potential impacts from new U.S. tariffs on pharmaceuticals. In Africa, central banks are increasingly turning to gold for economic stability, and several nations have experienced tragic aviation incidents.